Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Eur Urol. 2020 Mar 4;78(3):387–399. doi: 10.1016/j.eururo.2020.02.012

Fig. 4 –

Fig. 4 –

Forest plots of complete response rates of CIS-containing studies, recurrence-free rates (RFRs) of papillary-only studies; and disease-free rates (DFR) of studies accruing both CIS and papillary disease patients at 3, 6,12,18, and 24 mo following treatment initiation excluding studies with a high risk of bias. BCG = bacillus Calmette-Guérin; CR = complete response; EMDA = electromotive drug administration; IFNα = interferon alpha; i/ves = intravesical; MCNA = M. phlei cell wall–nucleic acid complex; MMC = mitomycin C.